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INTRODUCTION
Brain metastasis from breast cancer is less common than metastasis to the bone, lung, and liver. However, the prognosis of brain metastasis is very poor, with a median survival time ranging between 5.4 and 13 months. Additionally, it is usually discovered at a later stage during the systemic progression of breast cancer [1, 2] . While brain metastasis is generally observed in 10% to 20% of patients with metastatic breast cancers (MBC), autopsy series have revealed that it is, in fact, present in > 34% of patients [1, 3] . Current therapies for brain metastasis include whole brain radiotherapy (WBRT), surgery, stereotactic radiation therapy (SRT), corticosteroids, and systemic chemotherapy. WBRT is considered the standard treatment for metastatic brain tumors (MBT); the role of chemotherapy is still controversial owing to the difficulties associated with passage through the blood-brain barrier (BBB) [1, 2] .
Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product [4] . Halichondrin B binds to tubulin in the vinca domain, thereby inhibiting tubulin polymerization. However, unlike other tubulin polymerization inhibitors, halichondrin B does not function by inhibiting tubulin growth or by shortening the microtubule [5, 6] . Eribulin is currently acknowledged as a new line of therapy for MBC [7] . In a phase III study (eribulin monotherapy versus treatment of physician's choice in patients with MBC [EMBRACE]), eribulin treatment improved overall survival in patients with heavily pretreated MBC, but these studies included few patients with brain metastases [8] . Therefore, it is crucial to evaluate the effectiveness and safety of eribulin in the treatment of patients with breast cancer with brain metastasis. Herein, we report two cases of breast cancer with brain metastasis that were treated with eribulin mesylate combined with local treatment for MBT.
The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.
nodes, in Inje University Busan Paik Hospital in June 2013. The patient complained of headache and tinnitus but there were no neurologic symptoms. Magnetic resonance imaging (MRI) of her brain showed two metastatic lesions with edema at the cerebrum; the larger lesion measured 2.7× 2.1 cm ( Figure 1A) .
Five years earlier, in July 2008, the patient had undergone a left modified radical mastectomy for invasive ductal carcinoma. The pathologic stage of the disease was T3N3M0 and the histologic grade was low. The genetic subtype was luminal Blike human epidermal growth factor receptor 2 (HER2)-negative, which was positive for estrogen receptor (ER) and progesterone receptor (PR), negative for HER2, and the Ki-67 labeling index > 14%. The patient received adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by paclitaxel (doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 , every 3 weeks, intravenously for four cycles; followed by paclitaxel 175 mg/m 2 , every 3 weeks, intravenously for four cycles). Following the chemotherapy treatment, she received radiation therapy and tamoxifen.
Four years after the surgery, in May 2012, positron emission tomography (PET) revealed metastases in the patient's right lung, and in her paratracheal, subcarinal, and right supraclavicular lymph nodes, although she showed no symptoms or signs of either local or distant metastatic recurrence. A needle biopsy confirmed the presence of metastatic lesions from breast cancer in the right supraclavicular lymph node. The genetic subtype of the metastatic node was luminal B-like HER2-negative (ER-positive, PR-negative, HER2-negative, and Ki-67 labeling index > 14%). Based on the first-line palliative chemotherapy, the patient received docetaxel (75 mg/m (Figure 1B ), but the PET-computed tomography (CT) image showed increased glucose uptake and size in the metastatic lymph nodes of the mediastinum, indicating aggravation.
The patient received WBRT (total 3,000 cGy: 300 cGy/day for 10 days). She then received eribulin single therapy (1.4 g/m 2 on days 1 and 8, intravenously, every 3 weeks) 4 days later as third-line palliative chemotherapy in November 2013. At the 3-month follow-up appointment, after the fourth cycle of eribulin, the MBT had further decreased in size; the heterogeneous enhancing lesion decreased from 2.5 to 1.7 cm. Additionally, the oval-shaped cystic lesion had decreased from 1.5 to 0.8 cm (Figure 2A ). After the sixth cycle of eribulin treatment, the patient discontinued use owing to financial reasons; the eribulin therapy was restarted 3 months later. At the 8-month follow-up examination in July 2014, after the eighth cycle of eribulin treatment, the MBT showed regression with systematically stable disease ( Figure 2B ). The patient was still receiving eribulin and there were no severe hematologic or non-hematologic adverse events reported during or after the chemotherapy. At the 10-month follow-up examination in September 2014, following the tenth cycle of eribulin treatment, a PET-CT scan showed that the mediastinal nodes had increased in size and that glucose metabolism in these nodes had also increased. The MBT progressed systemically 12 months after eribulin single therapy in November 2014.
As the patient had the luminal B breast cancer subtype, and she was postmenopausal, we initiated treatment with an aromatase inhibitor (letrozole) in December 2014. In July 2015, we changed the regimen to everolimus plus exemestane due to systemic progression. The patient is still alive, without any neurologic symptoms, more than 24 months following the MBT diagnosis. , on days 1 and 8, every 3 weeks, intravenously) was started in August 2014. For further local treatment of the brain metastasis, the patient received WBRT (total 3,000 cGy: 250 cGy/day for 12 days) with a boost dose to the tumor bed (total 3,600 cGy: 300 cGy/day for 12 days). During the treatment period with eribulin, local wound dehiscence developed at the site of craniotomy in the scalp. To manage this, a local skin flap surgery was performed, and the eribulin treatment was temporally halted for 4 weeks. As of December 2015, the patient was on her 23rd cycle of eribulin, without tumor recurrence or progression in the brain or liver. Her last follow-up studies, including brain MRI and liver CT, carried out on November 20, 2015 revealed stable disease ( Figure 3B ). A B
DISCUSSION
The clinical regression, without symptoms, of MBT from breast cancer was sustained for 24 and 18 months in case 1 and case 2, respectively, using multimodality therapies that included surgery, SRT, WBRT, chemotherapy, and endocrine therapy. WBRT followed by eribulin induced a continuous decrease in the size of the MBT with systemic disease stability for 12 months in case 1. Surgery followed by eribulin with concurrent WBRT inhibited systemic progression for 18 months in case 2.
In order to effectively treat MBT, a chemotherapeutic agent should induce effective cytotoxicity in the tumor cells. It should be able to reach adequate concentrations, maintain this concentration in the tumor's extracellular space, and cross the BBB while evading active efflux mechanisms [2] . Compared with that of primary brain tumors, the BBB of MBT tends to be relatively permeable [9] . In addition, the expression of P-glycoprotein (P-gp), which is associated with permeability of the BBB, is decreased in MBT [10] . Furthermore, the permeability of the BBB can be increased by WBRT [11, 12] .
In line with our experience, a previous case report showed that eribulin therapy may be beneficial in the treatment of MBT arising from breast cancer [13] . In a patient with progression of brain and liver metastasis after WBRT followed by lapatinib and capecitabine treatment, eribulin achieved a significant response in the MBT 1 month later and this effect lasted for 4 months.
The following hypotheses could explain the mechanism of the therapeutic effect of eribulin on MBT in our cases: first, eribulin was efficacious against the systemic disease; second, WBRT may have facilitated the passage of eribulin across the BBB by decreasing the function of P-gp; third, the antiangiogenic action of eribulin could have increased the transmission of eribulin itself. A new mode of action for eribulin that involves remodeling of the tumor vasculature through a novel antivascular activity has already been reported [14] .
Eribulin may offer a clinical benefit in the treatment of MBT arising from breast cancer. WBRT followed by eribulin, or eribulin with concurrent WBRT may represent an effective treatment option for breast cancer patients with brain metastasis. Future studies are warranted to evaluate the precise effect of eribulin and its mechanism of action on brain metastasis.
